Relmada publishes investor presentation highlighting NDV-01 program for non-muscle invasive bladder cancer
I'm LongbridgeAI, I can summarize articles.Relmada Therapeutics published an investor presentation highlighting its lead program, NDV-01, for non-muscle invasive bladder cancer. Phase 2a TRCG-011 data showed a 95% anytime complete response rate and 76% at 12 months, with strong results in BCG-unresponsive patients. The drug demonstrated a favorable safety profile with no Grade 3+ adverse events. Relmada aims to file INDs by year-end 2026, initiating Phase 3 cohorts upon clearance.
- Relmada outlined NDV-01 as its lead program, a sustained-release intravesical gemcitabine/docetaxel candidate for non-muscle invasive bladder cancer. * Ongoing Phase 2a TRCG-011 high-risk NMIBC study showed 95% anytime complete response; 76% complete response at 12 months. * BCG-unresponsive subgroup showed 94% anytime complete response; 80% complete response at 12 months; no progression to muscle-invasive disease. * Safety update: no Grade 3 or higher treatment-related adverse events; 63% reported treatment-related events, mainly dysuria at 54%. * Development plan targets IND filings by year-end 2026 for NDV-01 and sepranolone; Phase 3 RESCUE registrational cohorts start upon IND clearance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here